Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Last November, Magenta Therapeutics ended a year of self-imposed startup silence with a hefty $48.5 million Series A and a burgeoning team of investigators focused on cord blood stem cell therapies. Today, just a little more than 5 months later, it’s adding $50 million in Series B cash from some marquee investors that includes the venture group formerly known as Google and in-licensing a mid-stage drug that Novartis clearly thinks highly of for enhancing cord blood stem cells as a treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
